The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| Alnylam | Common | 02043Q107 | 9,689 | 313,053 | SH | DFND | 1 | 313,053 | 0 | 0 | |
| Amarin | SPONS ADR | 023111206 | 46,827 | 8,087,486 | SH | DFND | 0 | 8,087,486 | 0 | 0 | |
| Anthera | Common | 03674U102 | 1,727 | 3,503,956 | SH | DFND | 0 | 3,503,956 | 0 | 0 | |
| Cempra | Common | 15130J109 | 5,593 | 714,285 | SH | DFND | 0 | 714,285 | 0 | 0 | |
| GW Pharma (US) | ADS | 36197T103 | 879 | 102,200 | SH | DFND | 0 | 102,200 | 0 | 0 | |
| Hyperion | Common | 44915N101 | 1,376 | 62,500 | SH | DFND | 0 | 62,500 | 0 | 0 | |
| Oncogenex Pharma | Common | 68230A106 | 5,917 | 603,740 | SH | DFND | 0 | 603,740 | 0 | 0 | |
| Portola | Common | 737010108 | 30,502 | 1,240,917 | SH | DFND | 1 | 1,240,917 | 0 | 0 | |
| Supernus | Common | 868459108 | 23,184 | 3,600,000 | SH | DFND | 1 | 3,600,000 | 0 | 0 | |
| Zalicus | Common | 98887C105 | 268 | 473,800 | SH | DFND | 0 | 473,800 | 0 | 0 | |
| Zogenix | Common | 98978L105 | 4,017 | 2,335,218 | SH | DFND | 1 | 2,335,218 | 0 | 0 | |